Darolutamide

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 545 publications

The emerging trends in prostate cancer treatment: a systematic review of the literature.

The emerging trends in prostate cancer treatment: a systematic review of the literature.

Journal: Journal of chemotherapy (Florence, Italy)

Published: August 20, 2026

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer.

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer.

Journal: JAMA network open

Published: August 19, 2026

Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer.

Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer.

Journal: JAMA oncology

Published: August 13, 2026

Commentary on "matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC".

Commentary on "matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC".

Journal: Future oncology (London, England)

Published: August 08, 2026

Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.

Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 03, 2026

Darolutamide-based triplet therapy versus androgen receptor pathway inhibitor-based doublet therapy for metastatic castration-sensitive prostate cancer: a real-world analysis using the TriNetX database.

Darolutamide-based triplet therapy versus androgen receptor pathway inhibitor-based doublet therapy for metastatic castration-sensitive prostate cancer: a real-world analysis using the TriNetX database.

Journal: Japanese journal of clinical oncology

Published: July 16, 2026

Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study.

Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study.

Journal: ESMO real world data and digital oncology

Published: July 13, 2026

Androgen Deprivation Therapy and Cardiovascular Health: Challenges and Opportunities in Prostate Cancer Care.

Androgen Deprivation Therapy and Cardiovascular Health: Challenges and Opportunities in Prostate Cancer Care.

Journal: Archivos espanoles de urologia

Published: July 13, 2026

Empirical-Null Calibration Challenges Comparative CNS Safety Signals for Androgen-Receptor Pathway Inhibitors: A FAERS Re-Analysis.

Empirical-Null Calibration Challenges Comparative CNS Safety Signals for Androgen-Receptor Pathway Inhibitors: A FAERS Re-Analysis.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 06, 2026

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Journal: Minerva urology and nephrology

Published: June 23, 2026

The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol.

The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol.

Journal: BMJ open

Published: June 18, 2026

The pseudouridine epitranscriptomic landscape of advanced prostate cancer therapeutic resistance identifies TIMM17A as a key player.

The pseudouridine epitranscriptomic landscape of advanced prostate cancer therapeutic resistance identifies TIMM17A as a key player.

Journal: Translational oncology

Published: May 25, 2026

Showing 1-12 of 545

Last Updated: 09/26/2026